Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: A pilot study

Veterinary Parasitology

Volumn 153, Issue 3-4, 2008, Pages 244-254

  Rougier, Sandrine ^a   Vouldoukis, Ioannis ^b   Fournel, Sandrine ^a   Pérès, Sylvie ^a   Woehrlé, Frédérique ^a  

^a Vétoquinol Laboratory   (France)

^b INSERM   (France)

Author keywords

Dogs; Efficacy; Marbofloxacin; Treatment duration; Visceral leishmaniosis

Indexed keywords

MARBOFLOXACIN;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; MACROPHAGE; MALE; NONHUMAN; PILOT STUDY; RECURRENT DISEASE; TREATMENT DURATION; VISCERAL LEISHMANIASIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; ENZYME INHIBITORS; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; LEISHMANIASIS, VISCERAL; MALE; PILOT PROJECTS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 42249092992     PISSN: 03044017     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetpar.2008.01.041     Document Type: Article

References (34)

1. Alberola J., Rodriguez A., Francino O., Roura X., Rivas L., and Andreu D. Safety and efficacy of antimicrobial peptides against naturally acquired leishmaniosis. Antimicrob. Agents Chemother. 48 (2004) 641-643
2. Alvar J., Molina R., San Andres M., Tesouro M., Nieto J., Vitutia M., Gonzalez F., San Andres M.D., Boggio J., Rodriguez F., Sainz A., and Escacenas C. Canine leishmaniosis: clinical, parasitological and entomological follow-up after chemotherapy. Ann. Trop. Med. Parasitol. 88 (1994) 371-378
3. Bianciardi P., Fasanella A., Manzillo V.F., Trotta T., Aceti A., Pagano A., Gradoni L., and Oliva G. The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniosis. Parasitol. Res. 93 (2004) 486-492
4. Bourdoiseau G., Hugnet C., Papierok G.M., and Lemesre J.L. La leishmaniose canine à Leishmania infantum: essais d'immunothérapie. Bull. Acad. Vét. France 157 (2004) 63-67
5. Cavaliero T., Arnold P., Mathis A., Glaus T., Hofmann-Lehmann R., and Deplazes P. Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum. J. Vet. Intern. Med. 13 (1999) 330-334
6. Chakraborty A.K., and Majumder H.K. Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochem. Biophys. Res. Commun. 152 (1988) 605-611
7. Chakraborty A.K., Gupta A., and Majumder H.K. A type 1 DNA topoisomerase from the kinetoplast hemoflagellate Leishmania donovani. Indian J. Biochem. Biophys. 30 (1993) 257-263
8. Dalhoff A., and Shalit I. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 3 (2003) 359-371
9. Denerolle P., and Bourdoiseau G. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of leishmaniosis (96 cases). J. Vet. Intern. Med. 13 (1999) 413-415
10. Furet Y.X., and Pechère J.C. Newly documented antimicrobial activity of quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 249-254
11. Ginel P.J., Lucena R., Lopez R., and Molleda J.M. Use of allopurinol for maintenance of remission in dogs with leishmaniosis. J. Small Anim. Pract. 39 (1998) 271-274
12. Koutinas A.F., Scott D.W., Kantos V., and Lekkas S. Skin lesions in canine leishmaniosis (Kala-Azar): a clinical and histopathological study on 22 spontaneous cases in Greece. Vet. Dermatol. 3 (1993) 121-130
13. Lefebvre H.P., Dupouy V., Schneider M., Laroute V., and Toutain P.L. Pharmacokinetics of marbofloxacin in renal impairment in the dog. Vet. Quart. 20 (1998) S104
14. Lefebvre H.P., Schneider M., Dupouy V., Laroute V., Costes G., Delesalle L., and Toutain P.L. Effect of experimental renal impairment on disposition of marbofloxacin and its metabolites in the dog. J. Vet. Pharmacol. Ther. 21 (1998) 453-461
15. Meunier D., Acar J.F., Martel J.L., Kroemer S., and Vallé M. A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets. Int. J. Antimicrob. Agents 24 (2004) 592-598
16. Miro G., Mateo M., Cruz I., Canavate C., Nieto J., Montoya A., Galy S., Medaille C., and Alvar J. Miltefosine: a new treatment for canine leishmaniosis. Proceedings of the 3rd World Congress on Leishmaniosis. Palermo, Sicily, Italy (2005) 171
17. Monjour L., Vouldoukis I., Debons-Guillemin M.C., Alfred C., Chopin C., Ploton I., Segovia M., and Roseto A. Application of an in vivo culture system for rapid demonstration of anti-Leishmania activity of monoclonal antibodies. Trans. Roy. Soc. Trop. Med. Hyg. 81 (1987) 210-211
18. Murray H.W., Oca M.J., Granger A.M., and Schreiber R.D. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniosis. J. Clin. Invest. 83 (1989) 1253-1257
19. Neogy A.B., Vouldoukis I., Da Costa J.M., and Monjour L. Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniosis. Veterinary group of Lupino. Vet. Parasitol. 54 (1994) 367-373
20. Noli C., and Auxilia S.T. Treatment of canine old world visceral leishmaniosis: a systematic review. Vet. Dermatol. 16 (2005) 213-232
21. Oliva G., Gradoni L., Cortese L., Orsini S., Ciaramella P., Scalone A., De Luna R., and Persechino A. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniosis. Ann. Trop. Med. Parasitol. 92 (1998) 165-171
22. Pennisi M.G., De Majo M., Masucci M., Britti D., Vitale F., and Del Maso R. Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin. Vet. Rec. 156 (2005) 346-349
23. Pinelli E., Gebhard D., Mommaas A.M., Van Hoeij M., Langermans J.A., Ruitenberg E.J., and Rutten V.P. Infection of a canine macrophage cell line with Leishmania infantum: determination of nitric oxide production and anti-leishmanial activity. Vet. Parasitol. 92 (2000) 181-189
24. Poli A., Sozzi S., Guidi G., Bandinelli P., and Mancianti F. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniosis. Vet. Parasitol. 71 (1997) 263-271
25. Prescott J.F., Desmond Baggot J., and Walker R.D. Fluoroquinolones. Antimicrobial Therapy in Veterinary Medicine. 3rd ed. (2000), Iowa State University Press/Ames, Iowa pp. 315-338
26. Raether W., Seidenath H., and Hofmann J. Potent antibacterial fluoroquinolones with marked activity against Leishmania donovani in vivo. Parasitol. Res. 75 (1989) 412-413
27. Rosypal A.C., Troy G.C., Gogal R., Zajac A.M., and Lindsay D.S. Emergence of zoonotic canine leishmaniosis in the United States: isolation and immunohistochemical detection of Leishmania infantum from foxhounds from Virginia. J. Eukaryot. Microbiol. 50 (2003) S691-S693
28. Rosypal A.C., Zajac A.M., Troy G.C., and Lindsay D.S. Infections in immunocompetent and immune deficient mice with promastigotes of a North American isolate of Leishmania infantum. Vet. Parasitol. 130 (2005) 19-27
29. Rosypal A.C., Gogal Jr. R.M., Zajac A.M., Troy G.C., and Lindsay D.S. Cellular immune responses in dogs experimentally infected with a North American isolate of Leishmania infantum. Vet. Parasitol. 131 (2005) 45-51
30. Sereno D., Guilvard E., Maquaire S., Cavaleyra M., Holzmuller P., Ouaissi A., and Lemesre J.L. Experimental studies on the evolution of antimony-resistant phenotype during the in vitro life cycle of Leishmania infantum: implications for the spread of chemoresistance in endemic areas. Acta Trop. 80 (2001) 195-205
31. Slunt K.M., Grace J.M., MacDonald T.L., and Pearson R.D. Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob. Agents Chemother. 40 (1996) 706-709
32. Vouldoukis I., Alfred C., Monjour L., Mazier D., Brandicourt O., Ploton I., Tselentis Y., Nzuzi K.K., and Gentilini M. Milieux de culture pour la production des formes promastigotes et amastigotes de Leishmania. Application au diagnostic sérologique et essais thérapeutiques. Ann. Parasitol. Hum. Comp. 61 (1986) 147-154
33. Vouldoukis I., Rougier S., Dugas B., Pino P., Mazier D., and Woehrlé F. Canine visceral leishmaniosis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vet. Parasitol. 135 (2006) 137-146
34. World Health Organization, 2002. Annex 3. Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates in 2001. In: The World Health Report 2002, p.192-197. World Health Organization, Geneva, Switzerland. [Online.] http://www.who.int/whr/2002/en/whr2002annex3.pdf.